Plans afoot to grow complex 3D human tumour microenvironment in the lab
A project is in the pipeline to grow a complex 3D tumour microenvironment in vitro.
A project has been awarded 2.43 million euros for the development of the first complex three-dimensional human 'tumour microenvironment' in the laboratory.
The funding was provided by the European Research Council to Queen Mary, University of London, in an effort to revolutionise the field of cancer cell research through bioengineering methods.
It is hoped that the creation of such tumour microenvironments will replace inadequate techniques where human cancer cells are grown in isolation on plastic surfaces.
Dubbed the CANBUILD project, it might also pave the way for better testing of new drugs that target the human tumour microenvironment.
The multi-disciplinary team involved in the study will make the most of the latest advances in tissue engineering, biomechanics, imaging and stem cell biology in the hopes of engineering a 3D human tumour in which the different cell types of the microenvironment will communicate, evolve and grow in vitro.
"Growing an in vitro model which contains all these types of cells will allow us to watch how the cells communicate and how the tumour grows, teaching us more about what is going on in this complex system and hopefully giving us a model we can test new drugs on," said Professor Fran Balkwill.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...